Targeting Selective Activation of M1 for the Treatment of Alzheimer's Disease: Further Chemical Optimization and Pharmacological Characterization of the M1 Positive Allosteric Modulator ML169

被引：34

作者：

Tarr, James C. ^{[1
,3
,4
]}

Turlington, Mark L. ^{[1
,3
,4
]}

Reid, Paul R. ^{[5
]}

Utley, Thomas J. ^{[1
,3
,4
]}

Sheffler, Douglas J. ^{[1
,3
]}

Cho, Hyekyung P. ^{[1
,3
,4
]}

Klar, Rebecca ^{[1
]}

Pancani, Tristano ^{[1
,3
]}

Klein, Michael T. ^{[1
,3
,4
]}

Bridges, Thomas M. ^{[1
,3
,4
]}

Morrison, Ryan D. ^{[1
,3
,4
]}

Blobaum, Anna L. ^{[1
,3
]}

Xiang, Zixui ^{[1
,3
]}

Daniels, J. Scott ^{[1
,3
,4
]}

Niswender, Colleen M. ^{[1
,3
,4
]}

Conn, P. Jeffrey ^{[1
,3
,4
]}

Wood, Michael R. ^{[1
,2
,3
,4
]}

Lindsley, Craig W. ^{[1
,2
,3
,4
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Med Ctr, Dept Chem, Nashville, TN 37232 USA

[3] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA

[4] Vanderbilt Univ, Med Ctr, Vanderbilt Specialized Chem Ctr Probe Dev MLPCN, Nashville, TN 37232 USA

[5] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Chem Biol Chem Synth Core, Nashville, TN 37232 USA

来源：

ACS CHEMICAL NEUROSCIENCE | 2012年 / 3卷 / 11期

关键词：

Muscarinic; acetylcholine; positive allosteric modulator (PAM); ML169; Alzheimer's disease (AD); medium spiny neurons (MSNs); MLPCN; MUSCARINIC ACETYLCHOLINE-RECEPTORS; CHOLINERGIC INTERNEURONS; BASAL GANGLIA; STRIATUM; AGONIST; XANOMELINE; EXCITABILITY; EXPRESSION; SYMPTOMS; PROTEINS;

D O I：

10.1021/cn300068s

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The M, muscarinic acetylcholine receptor is thought to play an important role in memory and cognition, making it a potential target for the treatment of Alzheimer's disease (AD) and schizophrenia. Moreover, M, interacts with BACE1 and regulates its proteosomal degradation, suggesting selective M-1 activation could afford both palliative cognitive benefit as well as disease modification in AD. A key challenge in targeting the muscarinic acetylcholine receptors is achieving mAChR subtype selectivity. Our lab has previously reported the M-1 selective positive allosteric modulator ML169. Herein we describe our efforts to further optimize this lead compound by preparing analogue libraries and probing novel scaffolds. We were able to identify several analogues that possessed submicromolar potency, with our best example displaying an EC50 of 310 nM. The new compounds maintained complete selectivity for the M-1 receptor over the other subtypes (M-2-M-5), displayed improved DMPK profiles, and potentiated the carbachol (CCh)-induced excitation in striatal MSNs. Selected analogues were able to potentiate CCh-mediated nonamyloidogenic APPs alpha release, further strengthening the concept that M-1 PAMs may afford a disease-modifying role in the treatment of AD.

引用

页码：884 / 895

页数：12

共 43 条

[1] Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice [J].

Anagnostaras, SG ;

Murphy, GG ;

Hamilton, SE ;

Mitchell, SL ;

Rahnama, NP ;

Nathanson, NM ;

Silva, AJ .

NATURE NEUROSCIENCE, 2003, 6 (01) :51-58

[2] Highly efficient monophosphine-based catalyst for the palladium-catalyzed Suzuki-Miyaura reaction of heteroaryl halides and heteroaryl boronic acids and esters [J].

Billingsley, Kelvin ;

Buchwald, Stephen L. .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2007, 129 (11) :3358-3366

[3] Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease [J].

Bodick, NC ;

Offen, WW ;

Levey, AI ;

Cutler, NR ;

Gauthier, SG ;

Satlin, A ;

Shannon, HE ;

Tollefson, GD ;

Rasmussen, K ;

Bymaster, FP ;

Hurley, DJ ;

Potter, WZ ;

Paul, SM .

ARCHIVES OF NEUROLOGY, 1997, 54 (04) :465-473

[4] Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats [J].

Brady, Ashley E. ;

Jones, Carrie K. ;

Bridges, Thomas M. ;

Kennedy, J. Phillip ;

Thompson, Analisa D. ;

Heiman, Justin U. ;

Breininger, Micah L. ;

Gentry, Patrick R. ;

Yin, Huiyong ;

Jadhav, Satyawan B. ;

Shirey, Jana K. ;

Conn, P. Jeffrey ;

Lindsley, Craig W. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (03) :941-953

[5] Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators [J].

Bridges, Thomas M. ;

Kennedy, J. Phillip ;

Hopkins, Corey R. ;

Conn, P. Jeffrey ;

Lindsley, Craig W. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (19) :5617-5622

[6] THE ANTIPSYCHOTIC POTENTIAL OF MUSCARINIC ALLOSTERIC MODULATION [J].

Bridges, Thomas M. ;

LeBois, Evan P. ;

Hopkins, Corey R. ;

Wood, Michael R. ;

Jones, Carrie K. ;

Conn, P. Jeffrey ;

Lindsley, Craig W. .

DRUG NEWS & PERSPECTIVES, 2010, 23 (04) :229-240

[7] Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: Development of a potent and highly selective M1 PAM [J].

Bridges, Thomas M. ;

Kennedy, J. Phillip ;

Noetzel, Meredith J. ;

Breininger, Micah L. ;

Gentry, Patrick R. ;

Conn, P. Jeffrey ;

Lindsley, Craig W. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (06) :1972-1975

[8]

Bymaster FP, 1997, DRUG DEVELOP RES, V40, P158, DOI 10.1002/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.3.CO

[9]

2-6

[10] M1 receptors play a central role in modulating AD-like pathology in transgenic mice [J].

Caccamo, A ;

Oddo, S ;

Billings, LM ;

Green, KN ;

Martinez-Coria, H ;

Fisher, A ;

LaFerla, FM .

NEURON, 2006, 49 (05) :671-682

← 1 2 3 4 5 →